Pillar 1 - FTO (new thread), page-1487

Hi II,

I actually haven’t - I’ve seen a number of a papers citing METTL3, METTL14 and WTAP upregulation or downregulation being present in various cancers, however none of them I’ve seen discuss in development of targetted drugs from these methylators.

Interestingly I came across a study showing that METTL3 was upregulated in AML cells:

https://www.researchgate.net/publication/326556665_METTL3_regulates_WTAP_protein_homeostasis

From what I understood, the study demonstrated that over expression of METTL3 positively resulted in an increase of WTAP. The study then goes on to suggest this ‘abberant’ WTAP expression may likely be the link to AML in this case.

Another study (below) seems to suggest that METTL3 also suppresses a tumor suppressant gene known as Adenomatous Polyposis Coli (APC) - this was observed in
esophageal cancer cells (ESCC).


https://www.nature.com/articles/s41467-021-23501-5

Mason is definitely correct in that there a myriad of different cancers that link to dysregulation of the methylase/demethylase pathways.